Epizyme (NASDAQ: EPZM) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
This table compares Epizyme and Intec Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Epizyme and Intec Pharma’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Epizyme||$8.01 million||107.25||-$110.21 million||($2.27)||-5.46|
|Intec Pharma||N/A||N/A||-$13.36 million||N/A||N/A|
Intec Pharma has lower revenue, but higher earnings than Epizyme.
Institutional and Insider Ownership
85.3% of Epizyme shares are owned by institutional investors. Comparatively, 40.2% of Intec Pharma shares are owned by institutional investors. 25.2% of Epizyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Epizyme has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Intec Pharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Epizyme and Intec Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Epizyme currently has a consensus price target of $23.00, suggesting a potential upside of 85.48%. Intec Pharma has a consensus price target of $12.00, suggesting a potential upside of 129.89%. Given Intec Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Intec Pharma is more favorable than Epizyme.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company’s lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.